David Shaw’s NovoCure NVCR Stock Holding History

David Shaw’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,700	Closed	-$281K	–	5029
2022 Q3	$281K	Buy	+3,700	New	+$289K	﹤0.01%	4327
2021 Q3	–	Sell	-10,000	Closed	-$2.22M	–	5140
2021 Q2	$2.22M	Hold	10,000	–	–	﹤0.01%	2839
2021 Q1	$1.32M	Sell	10,000 -10,900	-52%	-$1.72M	﹤0.01%	2899
2020 Q4	$3.62M	Buy	20,900 +10,900	+109%	+$1.49M	﹤0.01%	2120
2020 Q3	$1.11M	Hold	10,000	–	–	﹤0.01%	2790
2020 Q2	$593K	Hold	10,000	–	–	﹤0.01%	3248
2020 Q1	$673K	Hold	10,000	–	–	﹤0.01%	3030
2019 Q4	$843K	Buy	+10,000	New	+$807K	﹤0.01%	3094

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

David Shaw's NVCR Position: Q2 2026 in Review

David Shaw increased its NovoCure (NVCR) stake by 58% in Q2 2026, buying an estimated $5.68M and bringing the position to 1,022,480 shares worth $15.5M. The position accounts for 0.01% of the portfolio, ranked #1482.

David Shaw first reported a position in NVCR in Q4 2016 and has held it in 33 quarters since. The position peaked at $34.6M in Q2 2019. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

David Shaw held 1,022,480 shares of NovoCure worth $15.5M as of Q2 2026.
David Shaw bought 375,418 NovoCure shares in Q2 2026, an estimated $5.68M.
NovoCure made up 0.01% of David Shaw's portfolio in Q2 2026, its #1482 holding.
David Shaw first reported a position in NovoCure in Q4 2016 and has held it in 33 quarters since.
David Shaw's NovoCure position peaked at $34.6M in Q2 2019.
215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.